ERBB2 and breast carcinoma: The objective of this study was to evaluate the prognostic and predictive value of TILs in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy with or without anthracyclines combined with trastuzumab and pertuzumab in the TRAIN-2 trial.